What type of study is this?

September 28, 2025Open Access

Discontinuation of Long-Acting Injectable Cabotegravir-Rilpivirine in a Large Clinic Cohort

Key Points

One in six PWH discontinued long-acting injectable therapy within 18 months, highlighting adherence issues.
Common reasons for discontinuation included injection-related pain and concerns over virologic failure.
Alternatives provided post-discontinuation resulted in viral suppression for most participants.
Data collected from a large clinic cohort emphasizes the need for understanding real-world treatment adherence.

Abstract

Abstract Little is known about long-acting injectable cabotegravir-rilpvirine (CAB/RPV-LA) discontinuation outside clinical trials. In a large clinic cohort, one in six PWH discontinued CAB/RPV-LA over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for PWH with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation.

Discontinuation of Long-Acting Injectable Cabotegravir-Rilpivirine in a Large Clinic Cohort

Key Points

Abstract

Cite This Study

Also Consider

Also Consider